New York. AS investors await results from the first US clinical trials of the gene-editing system known as Crispr, scientists are focused on finding ways to administer it directly into humans, according to the technology's co-inventor, Jennifer Doudna. Right now ...
from Google Alert - health https://ift.tt/32BS6ly
via IFTTT
0 comments:
Post a Comment